Posted in | News | Nanomedicine | Nanobusiness

Arrowhead Research Invests $1 Million in Calando Pharmaceuticals

Arrowhead Research Corporation (NASDAQ: ARWR) (“the Company”) today announced that it has invested $1 million in its majority owned subsidiary, Calando Pharmaceuticals, and converted approximately $8M of Calando debt to Arrowhead into equity. Arrowhead now owns approximately 79% of Calando’s outstanding equity.

The investment and the debt conversion follow recent milestones achieved by Calando, including several notable first accomplishments in RNAi technology. These include proof of the first definitive systemic siRNA delivery and first to show RNAi mediated knockdown of target mRNA and protein in humans.

“We are committed to driving Calando’s value by completing the phase 1 trial for CALAA-01 and identifying the best indication for a phase 2 trial, while continuing to build relationships with potential partners,” said Christopher Anzalone, Arrowhead’s CEO. “We remain very excited about our clinical data and Calando’s ability to solve the most critical need of RNAi therapeutics, an effective and well tolerated delivery method. As we work to complete the current trial, we remain confident that additional data will better serve our partnering goals given the continued appetite for systemic RNAi delivery supported by solid clinical data.”

Pursuant a purchase agreement between Arrowhead and Calando, Arrowhead purchased approximately 60 million shares of preferred stock in Calando for $1 million in cash and the cancellation of $8 million in debt owed to Arrowhead by Calando.



Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Arrowhead Pharmaceutical. (2019, February 12). Arrowhead Research Invests $1 Million in Calando Pharmaceuticals. AZoNano. Retrieved on June 16, 2024 from

  • MLA

    Arrowhead Pharmaceutical. "Arrowhead Research Invests $1 Million in Calando Pharmaceuticals". AZoNano. 16 June 2024. <>.

  • Chicago

    Arrowhead Pharmaceutical. "Arrowhead Research Invests $1 Million in Calando Pharmaceuticals". AZoNano. (accessed June 16, 2024).

  • Harvard

    Arrowhead Pharmaceutical. 2019. Arrowhead Research Invests $1 Million in Calando Pharmaceuticals. AZoNano, viewed 16 June 2024,

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.